Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

January 10, 2025

Primary Completion Date

August 31, 2028

Study Completion Date

November 30, 2028

Conditions
Diffuse Large B-Cell Lymphoma
Interventions
DRUG

R-CMOP Regimen

Rituximab intravenous drip, Cyclophosphamide intravenous drip, Liposomal Mitoxantrone intravenous drip, Vincristine intravenous drip, Prednisone orally

DRUG

R-CHOP Regimen

Rituximab intravenous drip, Cyclophosphamide intravenous drip, Doxorubicinin intravenous drip, Vincristine intravenous drip, Prednisone orally

Trial Locations (10)

510060

RECRUITING

The Fifth Affiliated Hospital of Guangzhou Medical University., Guangzhou

Unknown

NOT_YET_RECRUITING

Fujian Provincial Cancer Hospital, Fuzhou

NOT_YET_RECRUITING

Gansu Provincial Cancer Hospital, Lanzhou

NOT_YET_RECRUITING

The Affiliated Hospital of Guangdong Medical University, Guangzhou

NOT_YET_RECRUITING

Shenzhen People's Hospital, Shenzhen

RECRUITING

The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai

NOT_YET_RECRUITING

Guangxi Zhuang Autonomous Region Cancer Hospital, Guilin

NOT_YET_RECRUITING

Ganzhou Cancer Hospital, Ganzhou

NOT_YET_RECRUITING

Jiangxi Provincial Cancer Hospital, Nanchang

NOT_YET_RECRUITING

Beijing Tongren Hospital, Beijing

All Listed Sponsors
lead

Sun Yat-sen University

OTHER